Friday, 16 Feb 2018

You are here

Mycophenolate and Steroids in Neuropsychiatric Lupus

Beyond diagnosis, management of neuropsychiatric lupus (NPSLE) can be challenging. Moreover, there are scant studies addressing optimal management. In this issue of Clinical Rheumatology, researchers show the efficacy of mycophenolate mofetil (MMF) and deflazacort in NPSLE.

They identified 140 patients with NPSLE; 88 fulfilled the inclusion criteria. Most were young (25.51 ± 7.82 years) and female, and the median duration of follow-up was 33 months (3–129 months).

Seizures were the most common NPSLE manifestation (42%). After removing patients antiphospholipid syndrome, it was shown that the remaining 70 patients improved 87% with therapy.

At last follow-up, 97.1% with detailed data had improved, while 2 patients had relapsed on this regimen. Side effects were significantly more common in patients on prednisolone as compared to those on deflazacort.

In patients with NPSLE, MMF along with tapering steroids is an efficacious combo in inducing remission and preventing relapse of disease.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Nailfold Capillaroscopy Portends Prognosis in Systemic Sclerosis

Two reports underscore the importance of nailfold capillaroscopy (NFC) in scleroderma and have shown that nailfold capillary drop out was significantly associated with mortality in systemic sclerosis.

Poor Prognosis of the MDA-5 Antibody in Dermatomyositis

Researchers from Hong Kong assessed the clinical associations seen with the anti-melanoma differentiation-associated gene 5 antibody (anti-MDA5 Ab) assay in consecutive patients with dermatomyositis (DM) and polymyositis (PM).

Twenty patients with either DM or PM who were followed in the Rheumatology Clinic of Kwong Wah Hospital, Hong Kong were recruited and underwent testing for the anti-MDA-5 antibody.

Inefficacy of Immunosuppressive Treatments in Systemic Sclerosis with ILD

EUSTAR study results published in Arthritis Research & Therapy show the current state of immunosuppressive use in systemic sclerosis patients with interstitial lung disease (SSc-ILD) to be ill-defined, but that liberal use of glucocorticoids (GC) in SSc-ILD should be discouraged.

ESRD Death Declines in Vasculitis Patients

 

In the past 2 decades, mortality from end-stage renal disease (ESRD) among U.S. patients with granulomatosis with polyangiitis (GPA) has declined significantly, a nationwide study found.

Stroke Risk Confirmed in SLE

The most common cerebrovascular events (CVEs) seen among a large cohort of patients with systemic lupus erythematosus (SLE) were stroke and transient ischemia, and the majority of these events were attributable to the disease itself, a multinational study determined.